USA-based PharmaJet has entered into a collaboration with Australia’s largest biotech firm CSL Limited (ASX: CSL) to enable Afluria influenza vaccine to be delivered with the PharmaJet Stratis needle-free jet injector, as soon as the 2013-2014 flu season. Adding PharmaJet jet injectors to the Afluria label will expand the delivery options for flu vaccine administration, thereby helping to broaden immunization coverage, the US firm said.
The Centers for Disease Control and Prevention (CDC) recommends an annual flu vaccination for all US citizens over 6 months old. Flu shots have proven to reduce illness, absenteeism and flu-related medical expenses. For many people, the fear of needles is enough to deter receiving a seasonal flu shot, despite the risk of contracting and spreading the illness.
CSL will seek US FDA approval for 2013-2014 flu season
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze